Redeye updates its estimates and valuation following Vitec releasing its Q1 2025 report. While sales roughly matched our projections, EBITA clearly missed what we pencilled in. Still, we judge several factors contributed to the profit miss looking worse than what underlying fundamentals suggest. We update our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/